POSTER PRESENTATION



Open Access

PReS-FINAL-2265: Tuberculosis in pediatric patients who are receiving anti-TNF agents

J Calzada-Hernández^{1*}, A Noguera Julian², S Ricart Campos¹, R Bou Torrent¹, E Iglesias Jiménez¹, MI González Fernández¹, J Sánchez Manubens¹, V Torrente Segarra¹, L Rozas Quesada², FJ Martín Carpi³, J Antón López¹

From 20th Pediatric Rheumatology European Society (PReS) Congress Ljubljana, Slovenia. 25-29 September 2013

Introduction

Adult patients receiving anti-TNF α treatment are at increased risk for developing tuberculosis (TB). Few data have been published in the pediatric population.

Objectives

We describe the occurrence of latent tuberculosis infection (LTI) and TB in children and adolescents treated with anti-TNF α agents.

Methods


Cohort observational study including pediatric patients receiving anti-TNF α agents in a tertiary-care pediatric hospital. LTI is ruled out by the implementation of anti-TNF α drugs by tuberculin skin test (TST) and, from March 2012, QuantiFERON Gold-In Tube[®] test (QTF). Along treatment, patients are evaluated periodically for TB using history and physical examination, but TST/QTF are not systematically repeated.

Results

The final cohort consisted of 261 anti-TNF α treatments in 221 patients (56.1% female), of whom 51.7%/31. %/17.2% treated with etanercept/adalimumab/infliximab, respectively, for a variety of rheumatic diseases (75.6%), inflammatory bowel disease (20.8%) and inflammatory eye diseases (3.6%). The mean(SD) age at diagnosis of the primary condition was 7.2(4.6) years and the duration of the disease before implementing the anti-TNF α agent was 3.0(3.3) years. The total follow-up time under anti-TNF α treatment was 614 patients-year; mean(SD) time per patient: 2.8(2.2) years.

¹Pediatric Rheumatology Unit, Pediatrics Department, Hospital Sant Joan de Déu, Esplugues de Llobregat (Barcelona), Spain

Full list of author information is available at the end of the article



Conclusion

In our study, the prevalence of LTI (1.4%) was similar to that reported in population screening studies in Spain and no incident cases of TB were observed.

Disclosure of interest

None declared.

Authors' details

¹Pediatric Rheumatology Unit, Pediatrics Department, Hospital Sant Joan de Déu, Esplugues de Llobregat (Barcelona), Spain. ²Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu, Esplugues de Llobregat (Barcelona), Spain. ³Pediatric Gastroenterology Department, Hospital Sant Joan de Déu, Esplugues de Llobregat (Barcelona), Spain.

Published: 5 December 2013

Cite this article as: Calzada-Hernández *et al.*: **PReS-FINAL-2265**: **Tuberculosis in pediatric patients who are receiving anti-TNF agents.** *Pediatric Rheumatology* 2013 **11**(Suppl 2):P255.



© 2013 Calzada-Hernández et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

doi:10.1186/1546-0096-11-S2-P255